Known GRIN Variants and Associated Information

Understanding GRIN Variants

Every person with GRIN-related neurodevelopmental disorder (GRIN-NDD) has a deeply personal story.

At the center of that story is a genetic variant, or change, in a GRIN gene that may affect how NMDA receptors function in that person's brain.

As researchers, clinicians, and families advance our understanding of GRIN-NDD, more variants are being identified and studied to learn how specific variants may influence NMDA receptor function and disease symptom presentation.

**This page was created to share known GRIN variants with reported functional testing outcomes.**

Our goal is to make this scientific knowledge more accessible to patients, families, healthcare professionals, researchers, and the broader GRIN-NDD community while supporting continued learning and collaboration across the field.

The history of GRIN Therapeutics

GRIN Therapeutics was founded when Dr. Pierandrea Muglia met the GRIN community at the 2019 CFERV Conference on GRIN Variants at Emory University, in Atlanta. Dr. Muglia came arrived knowing that radiprodil had a mechanism suggesting it might help patients with gain of function genetic variants in GRIN2B. What he didn’t expect was the maturity of the work produced by the GRIN community—from clinicians, researchers, advocates, and families working together. This inspired him to form GRIN Therapeutics to develop potential a treatment for the GRIN community. This passion has fed and inspired our small, patient-focused team. Early success in GRIN-NDD has spurred exploration into other neurodevelopmental disorders involving NMDA receptor dysregulation.

Leadership team

The GRIN Therapeutics leadership team was chosen for its deep domain expertise in advancing treatments for neurological disorders, particularly for those involving seizures, from early clinical development through regulatory approval and beyond.